Lobaplatin-TACE Combined with Radioactive¹²⁵I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma

Abstract

Asian Pac J Cancer Prev, 15 (13), [5155][5156][5157][5158][5159][5160] IntroductionPrimary hepatocellular carcinoma (HCC), with a climbing incidence year by year, is one of the most common malignant tumors and presents a spreading trend worldwide (Sherman, 2010). Current principal means for the treatment of HCC include surgical treatment (liver resection and liver transplantation), regional treatment (transcatheter arterial chemoembolization (TACE) and topical therapy (ablation therapy, etc.) (Bruix and Sherman, 2011;Forner et al., 2012;Shi et al., 2013). However, when the patients refer to the hospital, most of them have been at the latest stage and consequently few of them can undergo surgical treatment. Moreover, the recurrence rate of HCC is high. Its 5-year recurrence rate can be up to 80%, while less than 20% of the recurrent HCC can get a re-resection (Bruix and Sherman, 2011). Liver transplantation can be a favorable approach for the treatment of liver cancer in the final stage, but the donors are very scarce and the cost is huge. Ultimately, most of the patients have to receive regional or topical treatment. I seed implantation (TACE+ 125I group). After treatment, the local remission rates and postoperative complications of two groups were compared using the Pearson Chi-square test. Overall survival in the two groups was calculated using Kaplan-Meier survival curves and the differences were tested using Log-rank test. Results: There were 7 cases of complete response (CR), 13 of partial response (PR), 6 of stable disease (SD) and 17 of progressive disease (PD) in the TACE group, with 13 cases of CR, 9 of PR, 5 of SD and 5 of PD in the TACE+ 125

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

“…Its use, however, is limited by sometimes severe organ toxicity, especially neuro-and nephrotoxicity. Carboplatin shows a favorable spectrum of toxicity, with reversible myelosuppression being the dose-limiting toxicity (Deng et al, 2013;Huang et al, 2013;Peng et al, 2014;Wang et al, 2014;Wu et al, 2014;Zhao et al, 2014). Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin.…”

Asparagus Polysaccharide and Gum with Hepatic Artery Embolization Induces Tumor Growth and Inhibits Angiogenesis in an Orthotopic Hepatocellular Carcinoma Model

“…With regard to the embolic agent used in TACE for HCC, several studies have analyzed the efficacy of lipiodol (Idee and Guiu, 2013;Peng et al, 2014). Howerve, the adverse of TACE using lipiodol for HCC can not be ignored, due to the potential impairment of hepatic function among patients with poor liver function or a huge HCC that would require a large volume of lipiodol.…”

“…Transcatheter arterial chemoembolization (TACE) is an accepted treatment option for unresectable hepatocellular carcinoma (HCC) (Peng et al, 2014;Xu et al, 2014), of which equential TACE could an effective method to improve resection opportunity, expand the scope of surgical resection, as well as to greatly reduce postoperative intra-and extrahepatic metastasis (Xu et al, 2014). However, the long-term effectiveness of TACE remains limited.…”

“…These results highlighted the potent of aspartame polysaccharides and aspartame gum as the novel emboliaztion agents for clinical liver cancer TACE therapies. As combined chemotherapy drug with TACE (lobaplatin) can obtain significant clinical efficacy, and TACE combined with 125I seed implantation can better control the lesions and protect liver function for advanced HCC (Peng et al, 2014), it is worthy to expect the effective combinational usage of aspartame polysaccharides or aspartame gum for HCC TACE therapy.…”

New modalities of treatment for hepatocellular carcinoma

“…This combination has efficacy for advanced HCC. 158 In another study combination of (DEBs)-based TACE and SBRT was evaluated. OS was remarkably higher in the TACE + SBRT group compared with the TACE-only group (33 and 20 months, respectively; P = 0.02).…”